Pila Pharma Past Earnings Performance
Past criteria checks 0/6
Pila Pharma's earnings have been declining at an average annual rate of -15.2%, while the Pharmaceuticals industry saw earnings growing at 10.5% annually. Revenues have been growing at an average rate of 38.5% per year.
Key information
-15.2%
Earnings growth rate
13.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 30.5% |
| Revenue growth rate | 38.5% |
| Return on equity | -149.1% |
| Net Margin | -678.7% |
| Next Earnings Update | 27 Aug 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Pila Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 1 | -10 | 7 | 0 |
| 30 Sep 23 | 2 | -13 | 9 | 0 |
| 30 Jun 23 | 2 | -17 | 10 | 0 |
| 31 Mar 23 | 2 | -20 | 10 | 0 |
| 31 Dec 22 | 2 | -27 | 11 | 0 |
| 30 Sep 22 | 2 | -28 | 9 | 0 |
| 30 Jun 22 | 2 | -27 | 9 | 0 |
| 31 Mar 22 | 1 | -25 | 10 | 0 |
| 31 Dec 21 | 1 | -17 | 10 | 0 |
| 30 Sep 21 | 0 | -17 | 8 | 0 |
| 31 Dec 20 | 0 | -7 | 3 | 0 |
| 31 Dec 19 | 0 | -9 | 3 | 0 |
| 31 Dec 18 | 0 | -6 | 2 | 0 |
| 31 Dec 17 | 0 | -5 | 3 | 0 |
| 31 Dec 16 | 0 | -1 | 1 | 0 |
Quality Earnings: PILA is currently unprofitable.
Growing Profit Margin: PILA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PILA is unprofitable, and losses have increased over the past 5 years at a rate of 15.2% per year.
Accelerating Growth: Unable to compare PILA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PILA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.7%).
Return on Equity
High ROE: PILA has a negative Return on Equity (-149.07%), as it is currently unprofitable.